article Open AccessTop 1% cited

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Annals of Surgical Oncology · 2005 · Vol. 12(12) · pp. 1005–1016

Ajay V. Maker✉Giao Q. Phan(National Cancer Institute)Peter Attia(National Institutes of Health)James Chih‐Hsin Yang(National Cancer Institute)Richard M. Sherry(National Institutes of Health)Suzanne L. Topalian(National Institutes of Health)Udai S. Kammula(National Institutes of Health)Richard E. Royal(National Cancer Institute)Leah Haworth(National Institutes of Health)Catherine Lévy(National Cancer Institute)David E. Kleiner(National Cancer Institute)Sharon Mavroukakis(National Institutes of Health)Michael YellinSteven A. Rosenberg(National Institutes of Health)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology Immunotherapy and Immune ResponsesMedicineCTLA-4ImmunologyBlockadeCytotoxic T cellAntigenInternal medicineIpilimumabImmunotherapyMelanoma

MeSH terms

IpilimumabAdultAntibodies, MonoclonalAntigens, DifferentiationDrug Therapy, CombinationFemaleFlow CytometryHumansImmunosuppressive AgentsImmunotherapyInterleukin-2MaleMelanomaMiddle AgedSkin Neoplasms

Citations

489

FWCI

15.24

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma